2029, Chemotherapy and Immunity

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2029

Chemotherapy

Immunity

Daiichi Sankyo poised to add another ADC blockbuster with datopotamab deruxtecan for non-squamous NSCLC: GlobalData

Express Pharma

FEBRUARY 21, 2024

billion by 2029. “ billion by 2029. “ There are multiple Phase III studies for the ADC in frontline NSCLC in combination with immune checkpoint inhibitors such as Merck’s Keytruda (pembrolizumab) or AstraZeneca’s Imfinzi (durvalumab). billion in 2023, and GlobalData projects it to surpass $14 billion by 2029.

Chemotherapy

Chemotherapy Labelling Immunity Immunization

AstraZeneca acquires TeneoTwo in $1.3bn deal to broaden haematology portfolio

Pharmaceutical Technology

JULY 8, 2022

Moreover, a deeper understanding of immune evasion by cancer cells may provide novel sensitization strategies to further enhance the clinical response of BiTEs. . The confirmatory Phase III TOWER trial demonstrated superior overall survival in R/R B-ALL patients with Blincyto versus conventional chemotherapy (7.7 months vs. 4.0

Chemotherapy

Chemotherapy Immunity Immunization

Pharmacist Digest

Daiichi Sankyo poised to add another ADC blockbuster with datopotamab deruxtecan for non-squamous NSCLC: GlobalData

AstraZeneca acquires TeneoTwo in $1.3bn deal to broaden haematology portfolio

Stay Connected